| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 55 | 2022 | 762 | 3.670 |
Why?
|
| Inflammatory Bowel Diseases | 26 | 2022 | 580 | 2.680 |
Why?
|
| Colitis, Ulcerative | 27 | 2022 | 739 | 1.800 |
Why?
|
| Child | 76 | 2022 | 7174 | 1.100 |
Why?
|
| Anti-Inflammatory Agents | 6 | 2013 | 345 | 0.910 |
Why?
|
| Adolescent | 64 | 2019 | 9263 | 0.730 |
Why?
|
| Prednisone | 4 | 2012 | 259 | 0.720 |
Why?
|
| Immunosuppressive Agents | 12 | 2015 | 975 | 0.700 |
Why?
|
| Growth | 4 | 2007 | 43 | 0.700 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2015 | 237 | 0.650 |
Why?
|
| Gastritis | 3 | 2015 | 36 | 0.640 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2022 | 2340 | 0.570 |
Why?
|
| Gastrointestinal Agents | 7 | 2015 | 172 | 0.560 |
Why?
|
| Child, Preschool | 37 | 2019 | 3731 | 0.530 |
Why?
|
| Fever | 1 | 2015 | 128 | 0.480 |
Why?
|
| Mercaptopurine | 5 | 2013 | 53 | 0.460 |
Why?
|
| Bacterial Infections | 1 | 2015 | 184 | 0.450 |
Why?
|
| Blood Sedimentation | 3 | 2012 | 13 | 0.430 |
Why?
|
| Growth Disorders | 7 | 2008 | 63 | 0.420 |
Why?
|
| Thalidomide | 1 | 2012 | 57 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 5 | 2013 | 1412 | 0.390 |
Why?
|
| Fistula | 1 | 2012 | 42 | 0.390 |
Why?
|
| Humans | 96 | 2022 | 89357 | 0.370 |
Why?
|
| Female | 59 | 2022 | 46202 | 0.370 |
Why?
|
| Gastroenterology | 4 | 2003 | 144 | 0.360 |
Why?
|
| Intestines | 2 | 2012 | 416 | 0.320 |
Why?
|
| Male | 55 | 2019 | 42411 | 0.310 |
Why?
|
| Azathioprine | 5 | 2013 | 124 | 0.310 |
Why?
|
| Severity of Illness Index | 12 | 2018 | 1840 | 0.290 |
Why?
|
| Hospitalization | 2 | 2018 | 877 | 0.290 |
Why?
|
| Neutrophils | 2 | 2019 | 308 | 0.280 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2006 | 5 | 0.280 |
Why?
|
| Aneurysm, Infected | 1 | 2006 | 12 | 0.280 |
Why?
|
| Infant | 22 | 2019 | 3160 | 0.280 |
Why?
|
| Nutritional Status | 4 | 2008 | 80 | 0.280 |
Why?
|
| Mesenteric Arteries | 1 | 2006 | 29 | 0.280 |
Why?
|
| Dysbiosis | 2 | 2018 | 78 | 0.270 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 54 | 0.270 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2018 | 25 | 0.270 |
Why?
|
| Immunologic Factors | 1 | 2007 | 171 | 0.250 |
Why?
|
| Treatment Outcome | 11 | 2015 | 8241 | 0.250 |
Why?
|
| Age of Onset | 6 | 2019 | 312 | 0.240 |
Why?
|
| Infliximab | 5 | 2017 | 159 | 0.240 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 3666 | 0.240 |
Why?
|
| Chronic Disease | 10 | 2016 | 950 | 0.230 |
Why?
|
| Child Nutrition Disorders | 1 | 2003 | 12 | 0.220 |
Why?
|
| Health Services | 1 | 2003 | 57 | 0.210 |
Why?
|
| Menarche | 1 | 2022 | 29 | 0.210 |
Why?
|
| Research | 3 | 2006 | 252 | 0.210 |
Why?
|
| Age Factors | 6 | 2018 | 1870 | 0.200 |
Why?
|
| Gastrointestinal Diseases | 2 | 2003 | 151 | 0.200 |
Why?
|
| Thioguanine | 1 | 2001 | 17 | 0.200 |
Why?
|
| Constriction, Pathologic | 4 | 2021 | 217 | 0.200 |
Why?
|
| Prospective Studies | 8 | 2019 | 4289 | 0.200 |
Why?
|
| Child Nutritional Physiological Phenomena | 5 | 2008 | 12 | 0.190 |
Why?
|
| Nutritional Support | 2 | 1998 | 16 | 0.190 |
Why?
|
| Disease Progression | 6 | 2018 | 1489 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2022 | 2401 | 0.190 |
Why?
|
| Ileum | 2 | 2018 | 160 | 0.190 |
Why?
|
| Pedigree | 4 | 2019 | 970 | 0.190 |
Why?
|
| Immunoglobulin A | 3 | 2017 | 83 | 0.180 |
Why?
|
| Drug Therapy, Combination | 6 | 2007 | 784 | 0.180 |
Why?
|
| Mutation, Missense | 2 | 2019 | 277 | 0.180 |
Why?
|
| Cohort Studies | 10 | 2021 | 2872 | 0.180 |
Why?
|
| Jews | 2 | 2019 | 42 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 244 | 0.170 |
Why?
|
| Methotrexate | 2 | 2013 | 250 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 1999 | 55 | 0.170 |
Why?
|
| Aging | 2 | 2018 | 718 | 0.170 |
Why?
|
| Cytokine Receptor Common beta Subunit | 1 | 2019 | 1 | 0.170 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 7 | 0.170 |
Why?
|
| Wound Healing | 1 | 2021 | 359 | 0.160 |
Why?
|
| alpha-Defensins | 1 | 2018 | 2 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2019 | 82 | 0.160 |
Why?
|
| Remission Induction | 4 | 2007 | 740 | 0.160 |
Why?
|
| Peyer's Patches | 1 | 2018 | 18 | 0.160 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 112 | 0.160 |
Why?
|
| Bone Density | 2 | 2008 | 209 | 0.160 |
Why?
|
| Case-Control Studies | 8 | 2019 | 1862 | 0.160 |
Why?
|
| Adalimumab | 3 | 2017 | 86 | 0.160 |
Why?
|
| Breast Feeding | 2 | 2018 | 102 | 0.150 |
Why?
|
| Antibodies, Fungal | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2018 | 30 | 0.150 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2017 | 21 | 0.150 |
Why?
|
| Primary Prevention | 1 | 1998 | 82 | 0.150 |
Why?
|
| Phenobarbital | 1 | 1997 | 33 | 0.150 |
Why?
|
| NADPH Oxidases | 1 | 2018 | 82 | 0.150 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 100 | 0.150 |
Why?
|
| Adult | 21 | 2019 | 26607 | 0.140 |
Why?
|
| Gene Expression | 1 | 2021 | 1310 | 0.140 |
Why?
|
| Serum Albumin | 4 | 2012 | 127 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2018 | 158 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 1998 | 200 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 969 | 0.140 |
Why?
|
| HLA-DRB1 Chains | 1 | 2016 | 25 | 0.140 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2016 | 30 | 0.140 |
Why?
|
| Periodicity | 1 | 1997 | 119 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2015 | 157 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 117 | 0.140 |
Why?
|
| Quality of Life | 3 | 2015 | 1668 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 65 | 0.130 |
Why?
|
| Yersinia Infections | 1 | 2016 | 5 | 0.130 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Bacterial Typing Techniques | 1 | 2016 | 28 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 1997 | 131 | 0.130 |
Why?
|
| Yersinia enterocolitica | 1 | 2016 | 18 | 0.130 |
Why?
|
| United States Food and Drug Administration | 1 | 1996 | 135 | 0.130 |
Why?
|
| Young Adult | 5 | 2019 | 6312 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2018 | 322 | 0.130 |
Why?
|
| Problem Solving | 2 | 2015 | 54 | 0.130 |
Why?
|
| Vomiting | 1 | 1997 | 195 | 0.130 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 1995 | 24 | 0.130 |
Why?
|
| Helicobacter Infections | 1 | 1995 | 37 | 0.130 |
Why?
|
| Helicobacter pylori | 1 | 1995 | 37 | 0.130 |
Why?
|
| Exome | 1 | 2016 | 127 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 2000 | 79 | 0.130 |
Why?
|
| Prevalence | 1 | 2019 | 1243 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 490 | 0.120 |
Why?
|
| Sexual Maturation | 3 | 1991 | 35 | 0.120 |
Why?
|
| Retrospective Studies | 8 | 2012 | 9057 | 0.120 |
Why?
|
| Smoking | 1 | 2018 | 621 | 0.120 |
Why?
|
| Intestinal Mucosa | 3 | 2016 | 805 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 825 | 0.120 |
Why?
|
| Pediatrics | 2 | 2006 | 353 | 0.120 |
Why?
|
| Transcriptome | 1 | 2019 | 630 | 0.120 |
Why?
|
| Medication Adherence | 1 | 2015 | 140 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2284 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 573 | 0.110 |
Why?
|
| Mass Screening | 1 | 1998 | 636 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 423 | 0.110 |
Why?
|
| Th1 Cells | 2 | 2018 | 166 | 0.110 |
Why?
|
| Hypoalbuminemia | 1 | 2012 | 9 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 788 | 0.110 |
Why?
|
| Biopsy | 3 | 2015 | 1184 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 152 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 1995 | 282 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2017 | 509 | 0.100 |
Why?
|
| Prognosis | 6 | 2019 | 3783 | 0.100 |
Why?
|
| Drug Hypersensitivity | 2 | 2005 | 37 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 1597 | 0.100 |
Why?
|
| Infant, Newborn | 7 | 2018 | 2486 | 0.100 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2012 | 88 | 0.100 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 1991 | 5 | 0.100 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2012 | 63 | 0.100 |
Why?
|
| Risk Factors | 8 | 2018 | 5499 | 0.100 |
Why?
|
| Biomarkers | 1 | 2017 | 1767 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2012 | 91 | 0.090 |
Why?
|
| Weight Loss | 1 | 2012 | 227 | 0.090 |
Why?
|
| Duodenal Diseases | 2 | 2006 | 23 | 0.090 |
Why?
|
| Microbiota | 1 | 2016 | 402 | 0.090 |
Why?
|
| Cisapride | 2 | 2000 | 4 | 0.090 |
Why?
|
| Time Factors | 5 | 2018 | 5338 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 895 | 0.090 |
Why?
|
| North America | 2 | 2018 | 184 | 0.090 |
Why?
|
| Growth Hormone | 2 | 2008 | 96 | 0.090 |
Why?
|
| Genetic Linkage | 3 | 2000 | 624 | 0.080 |
Why?
|
| Genome-Wide Association Study | 4 | 2022 | 1671 | 0.080 |
Why?
|
| Body Height | 6 | 2008 | 100 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2018 | 519 | 0.080 |
Why?
|
| Folic Acid Deficiency | 1 | 2008 | 7 | 0.080 |
Why?
|
| Stomatitis, Aphthous | 1 | 2009 | 4 | 0.080 |
Why?
|
| Genetic Variation | 2 | 2009 | 1374 | 0.080 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2010 | 127 | 0.080 |
Why?
|
| Somatomedins | 2 | 1986 | 28 | 0.080 |
Why?
|
| Nutritional Requirements | 1 | 1988 | 17 | 0.080 |
Why?
|
| Folic Acid | 1 | 2008 | 63 | 0.080 |
Why?
|
| Arthritis | 1 | 2009 | 47 | 0.080 |
Why?
|
| Puberty | 2 | 2018 | 60 | 0.080 |
Why?
|
| Sulfasalazine | 3 | 1994 | 34 | 0.080 |
Why?
|
| Anthropometry | 2 | 2003 | 75 | 0.080 |
Why?
|
| Recurrence | 4 | 1999 | 1144 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 699 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2002 | 575 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2008 | 147 | 0.070 |
Why?
|
| Middle Aged | 4 | 2019 | 25974 | 0.070 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 10 | 0.070 |
Why?
|
| Phenotype | 3 | 2018 | 2440 | 0.070 |
Why?
|
| United States | 8 | 2015 | 6989 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1986 | 114 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2008 | 451 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2001 | 683 | 0.070 |
Why?
|
| Tacrolimus | 2 | 2012 | 369 | 0.070 |
Why?
|
| Angiography | 1 | 2006 | 208 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2006 | 138 | 0.060 |
Why?
|
| Histamine H1 Antagonists | 1 | 2005 | 40 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 299 | 0.060 |
Why?
|
| Premedication | 1 | 2005 | 58 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2018 | 727 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2661 | 0.060 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2005 | 48 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 158 | 0.060 |
Why?
|
| Propensity Score | 2 | 2017 | 147 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2008 | 322 | 0.060 |
Why?
|
| Amyloidosis | 1 | 1986 | 127 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1942 | 0.060 |
Why?
|
| Cytokines | 1 | 2008 | 803 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 1991 | 1180 | 0.060 |
Why?
|
| Intestinal Obstruction | 2 | 2017 | 89 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 599 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 838 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 358 | 0.050 |
Why?
|
| Lactose Intolerance | 1 | 1981 | 2 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1994 | 266 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1431 | 0.050 |
Why?
|
| Incidence | 3 | 2012 | 1595 | 0.050 |
Why?
|
| Body Weight | 3 | 1998 | 452 | 0.050 |
Why?
|
| Leukopenia | 1 | 2001 | 66 | 0.050 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 51 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2001 | 223 | 0.050 |
Why?
|
| Food, Fortified | 1 | 1981 | 15 | 0.050 |
Why?
|
| Lactobacillus | 1 | 2000 | 21 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2008 | 1714 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 248 | 0.050 |
Why?
|
| Alleles | 3 | 2018 | 1135 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2001 | 254 | 0.050 |
Why?
|
| Intestinal Diseases | 3 | 2006 | 79 | 0.040 |
Why?
|
| Probiotics | 1 | 2000 | 88 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 1999 | 44 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 387 | 0.040 |
Why?
|
| Nutrition Disorders | 2 | 1989 | 15 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2015 | 2624 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1998 | 65 | 0.040 |
Why?
|
| Colonoscopy | 2 | 1998 | 279 | 0.040 |
Why?
|
| Databases as Topic | 1 | 1998 | 94 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 1998 | 68 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1998 | 48 | 0.040 |
Why?
|
| Aneuploidy | 1 | 1998 | 57 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1998 | 54 | 0.040 |
Why?
|
| Radius | 1 | 1998 | 31 | 0.040 |
Why?
|
| Liver | 2 | 2001 | 1208 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1998 | 100 | 0.040 |
Why?
|
| Medical Records | 1 | 1998 | 120 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2002 | 856 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 123 | 0.040 |
Why?
|
| Registries | 3 | 2008 | 784 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 1998 | 90 | 0.040 |
Why?
|
| Hormones | 1 | 1998 | 139 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2001 | 681 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2017 | 2303 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.040 |
Why?
|
| Fructose Intolerance | 1 | 1996 | 2 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 1997 | 40 | 0.040 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2016 | 16 | 0.040 |
Why?
|
| Sorting Nexins | 1 | 2016 | 5 | 0.040 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2016 | 5 | 0.040 |
Why?
|
| Tenascin | 1 | 2016 | 9 | 0.040 |
Why?
|
| Receptors, CXCR6 | 1 | 2016 | 6 | 0.040 |
Why?
|
| Reference Values | 1 | 1998 | 661 | 0.040 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2016 | 5 | 0.040 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2016 | 12 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2016 | 31 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 51 | 0.030 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 1996 | 73 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 36 | 0.030 |
Why?
|
| Myotonia | 1 | 1976 | 3 | 0.030 |
Why?
|
| Dysgammaglobulinemia | 1 | 1976 | 4 | 0.030 |
Why?
|
| Eyelid Diseases | 1 | 1976 | 6 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 75 | 0.030 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1976 | 47 | 0.030 |
Why?
|
| Adenylyl Cyclases | 1 | 2016 | 100 | 0.030 |
Why?
|
| Colonic Diseases | 1 | 1996 | 61 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 233 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 69 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Laryngeal Diseases | 1 | 1976 | 21 | 0.030 |
Why?
|
| Chromosome Mapping | 3 | 2009 | 1076 | 0.030 |
Why?
|
| Amoxicillin | 1 | 1995 | 12 | 0.030 |
Why?
|
| Joint Diseases | 1 | 1976 | 48 | 0.030 |
Why?
|
| Bismuth | 1 | 1995 | 8 | 0.030 |
Why?
|
| Metronidazole | 1 | 1995 | 26 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 787 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 1996 | 115 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2018 | 695 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1976 | 72 | 0.030 |
Why?
|
| Intraocular Pressure | 2 | 1992 | 57 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 308 | 0.030 |
Why?
|
| Colon | 1 | 2018 | 510 | 0.030 |
Why?
|
| Pancreas | 1 | 1996 | 246 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 630 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1072 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 242 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1976 | 111 | 0.030 |
Why?
|
| Parenteral Nutrition | 2 | 1988 | 63 | 0.030 |
Why?
|
| Pneumonia | 1 | 1976 | 182 | 0.030 |
Why?
|
| Colectomy | 1 | 1996 | 172 | 0.030 |
Why?
|
| Feces | 1 | 2016 | 330 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 253 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 682 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 40 | 0.030 |
Why?
|
| Energy Intake | 2 | 1986 | 97 | 0.030 |
Why?
|
| Aminosalicylic Acids | 1 | 1993 | 41 | 0.030 |
Why?
|
| Calcium | 1 | 1998 | 1175 | 0.030 |
Why?
|
| Gastritis, Hypertrophic | 1 | 1992 | 4 | 0.030 |
Why?
|
| Infant Food | 1 | 1992 | 11 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1993 | 225 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2012 | 53 | 0.030 |
Why?
|
| Hematocrit | 2 | 2008 | 68 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1265 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 481 | 0.030 |
Why?
|
| Breath Tests | 2 | 1982 | 57 | 0.030 |
Why?
|
| Prednisolone | 1 | 1992 | 40 | 0.030 |
Why?
|
| Cyclosporine | 1 | 2012 | 237 | 0.020 |
Why?
|
| Pregnancy | 2 | 2018 | 3018 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2017 | 0.020 |
Why?
|
| Child Development | 1 | 2013 | 167 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1993 | 590 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 1992 | 103 | 0.020 |
Why?
|
| Food Hypersensitivity | 1 | 1992 | 71 | 0.020 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 1991 | 6 | 0.020 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 1991 | 8 | 0.020 |
Why?
|
| Cataract | 1 | 1992 | 86 | 0.020 |
Why?
|
| Endoscopy | 1 | 1994 | 350 | 0.020 |
Why?
|
| Digestive System | 1 | 1990 | 42 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 2001 | 0.020 |
Why?
|
| Intestine, Small | 1 | 1992 | 299 | 0.020 |
Why?
|
| Family | 1 | 2012 | 325 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1991 | 134 | 0.020 |
Why?
|
| Intestinal Fistula | 1 | 2010 | 31 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1976 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1990 | 27 | 0.020 |
Why?
|
| Granuloma | 2 | 2006 | 65 | 0.020 |
Why?
|
| Lod Score | 2 | 2000 | 152 | 0.020 |
Why?
|
| Stomach Diseases | 1 | 1989 | 19 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2008 | 13 | 0.020 |
Why?
|
| Endocrine System | 1 | 2008 | 17 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 19165 | 0.020 |
Why?
|
| Enema | 1 | 1988 | 39 | 0.020 |
Why?
|
| Barium Sulfate | 1 | 1988 | 43 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2008 | 47 | 0.020 |
Why?
|
| Body Composition | 1 | 2008 | 71 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 114 | 0.020 |
Why?
|
| Body Image | 1 | 2008 | 78 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 130 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 130 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2001 | 922 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 1012 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 691 | 0.020 |
Why?
|
| Stomach | 3 | 1992 | 111 | 0.020 |
Why?
|
| Thyroid Diseases | 1 | 1986 | 105 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 1901 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2005 | 51 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2007 | 326 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2005 | 92 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 767 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2005 | 302 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2001 | 3027 | 0.010 |
Why?
|
| Demography | 1 | 2005 | 183 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1988 | 1719 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 1986 | 319 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 851 | 0.010 |
Why?
|
| Triolein | 1 | 1982 | 1 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 1214 | 0.010 |
Why?
|
| Palmitic Acids | 1 | 1982 | 8 | 0.010 |
Why?
|
| Caprylates | 1 | 1982 | 11 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11761 | 0.010 |
Why?
|
| Lactose | 1 | 1981 | 27 | 0.010 |
Why?
|
| Milk | 1 | 1981 | 53 | 0.010 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2001 | 13 | 0.010 |
Why?
|
| Triglycerides | 1 | 1982 | 232 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2000 | 6 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 204 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2001 | 112 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 27371 | 0.010 |
Why?
|
| Contraindications | 1 | 2000 | 70 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1981 | 124 | 0.010 |
Why?
|
| Permeability | 1 | 2000 | 137 | 0.010 |
Why?
|
| Taste | 1 | 1980 | 28 | 0.010 |
Why?
|
| Cytosine | 1 | 2001 | 128 | 0.010 |
Why?
|
| Heterozygote | 1 | 2001 | 373 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 149 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 293 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 1999 | 42 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2001 | 740 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2001 | 685 | 0.010 |
Why?
|
| Anorexia Nervosa | 1 | 1980 | 142 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1999 | 79 | 0.010 |
Why?
|
| Celiac Disease | 1 | 1982 | 214 | 0.010 |
Why?
|
| Algorithms | 1 | 2007 | 1877 | 0.010 |
Why?
|
| Radiography | 2 | 1992 | 809 | 0.010 |
Why?
|
| Diet | 1 | 1981 | 442 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 466 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2000 | 871 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1999 | 199 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 2062 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1998 | 200 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 2327 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 478 | 0.010 |
Why?
|
| Glucose Transporter Type 5 | 1 | 1996 | 6 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 28 | 0.010 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1977 | 18 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 2496 | 0.010 |
Why?
|
| Point Mutation | 1 | 1996 | 245 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1308 | 0.010 |
Why?
|
| Sex Factors | 1 | 1978 | 1066 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 451 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 1047 | 0.010 |
Why?
|
| Physicians, Women | 1 | 1975 | 56 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 1849 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 866 | 0.010 |
Why?
|
| Duodenoscopy | 1 | 1992 | 8 | 0.010 |
Why?
|
| Obstetrics | 1 | 1975 | 123 | 0.010 |
Why?
|
| Consanguinity | 1 | 1992 | 73 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1992 | 152 | 0.010 |
Why?
|
| Ocular Hypertension | 1 | 1992 | 8 | 0.010 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1992 | 11 | 0.010 |
Why?
|
| Glaucoma | 1 | 1992 | 33 | 0.010 |
Why?
|
| Palmitates | 1 | 1991 | 15 | 0.010 |
Why?
|
| Carnitine | 1 | 1991 | 14 | 0.010 |
Why?
|
| Muscles | 1 | 1991 | 193 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1991 | 511 | 0.010 |
Why?
|
| Pain Measurement | 1 | 1992 | 329 | 0.010 |
Why?
|
| Duodenum | 1 | 1990 | 103 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1992 | 266 | 0.010 |
Why?
|
| Esophagus | 1 | 1990 | 106 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1992 | 712 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 360 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1991 | 388 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1975 | 645 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1993 | 1719 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1989 | 41 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 1989 | 102 | 0.000 |
Why?
|
| Myocardium | 1 | 1991 | 571 | 0.000 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 1982 | 8 | 0.000 |
Why?
|
| Carbon Isotopes | 1 | 1982 | 74 | 0.000 |
Why?
|
| Biliary Tract Diseases | 1 | 1982 | 36 | 0.000 |
Why?
|
| Palmitic Acid | 1 | 1982 | 27 | 0.000 |
Why?
|
| Dysgeusia | 1 | 1980 | 1 | 0.000 |
Why?
|
| Carotenoids | 1 | 1980 | 15 | 0.000 |
Why?
|
| Hair | 1 | 1980 | 56 | 0.000 |
Why?
|
| Copper | 1 | 1980 | 78 | 0.000 |
Why?
|
| Zinc | 1 | 1980 | 93 | 0.000 |
Why?
|
| Iron | 1 | 1980 | 168 | 0.000 |
Why?
|
| Sulfapyridine | 1 | 1977 | 2 | 0.000 |
Why?
|
| Dermatitis Herpetiformis | 1 | 1977 | 9 | 0.000 |
Why?
|
| Mother-Child Relations | 1 | 1975 | 26 | 0.000 |
Why?
|
| Weaning | 1 | 1975 | 25 | 0.000 |
Why?
|
| Postnatal Care | 1 | 1975 | 27 | 0.000 |
Why?
|
| Culture | 1 | 1975 | 53 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1977 | 465 | 0.000 |
Why?
|
| Prenatal Care | 1 | 1975 | 77 | 0.000 |
Why?
|
| Breast Diseases | 1 | 1975 | 100 | 0.000 |
Why?
|
| Adaptation, Psychological | 1 | 1975 | 166 | 0.000 |
Why?
|
| Skin | 1 | 1977 | 582 | 0.000 |
Why?
|
| Counseling | 1 | 1975 | 164 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1975 | 327 | 0.000 |
Why?
|
| Patient Education as Topic | 1 | 1975 | 360 | 0.000 |
Why?
|
| Physician-Patient Relations | 1 | 1975 | 625 | 0.000 |
Why?
|